Trial Profile

A pharmacoeconomic study evaluating the cost-effectiveness of using the investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent in combination with granulocyte colony stimulating factor (G-CSF), against plerixafor in combination with G-CSF, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Granulocyte colony-stimulating factors (Primary) ; Motixafortide (Primary) ; Plerixafor (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

03 Nov 2022 According to a BioLineRx media release, results from this trial will be presented at the 64th American Society of Hematology (ASH) Annual Meeting 2022.
03 Nov 2022 Results published in the BioLineRx Media Release.
09 Mar 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com